Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway

Life Sciences

Volumn 195, Issue , 2018, Pages 87-94

  Xu, Xuejuan ^a,b,c   Chen, Jinsong ^a   Hu, Lidong ^a   Liang, Ming ^a   Wang, Xiaozhou ^a   Feng, Si ^a   Shen, Jie ^c   Luan, Xiaojun ^a  

^a THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

cAMP PKA signal pathway; Cell apoptosis; Cell secretion; Cell viability; Liraglutide; miR 375

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON; INSULIN; LIRAGLUTIDE; MICRORNA 375; ANTIDIABETIC AGENT; MICRORNA; MIRN375 MICRORNA, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CAMP PKA SIGNALING; CELL PROLIFERATION; CELL VIABILITY; CELLULAR SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; GLUCAGON RELEASE; IN VITRO STUDY; INSULIN RELEASE; METABOLIC INHIBITION; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLUCAGON; GLUCAGON-SECRETING CELLS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MICE; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 85040332833     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2017.12.012     Document Type: Article

References (39)

1. Nauck, M.A., Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124 (2011), S3–18.
2. Tran, K.L., Park, Y.I., Pandya, S., Muliyil, N.J., Jensen, B.D., Huynh, K., Nguyen, Q.T., Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am. Health Drug Benefits 10 (2017), 178–188.
3. Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., Yu, P., Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. 8, 2017, Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders, 727–738.
4. Kimura, T., Obata, A., Shimoda, M., Okauchi, S., Hirukawa, H., Kohara, K., Kinoshita, T., Nogami, Y., Nakanishi, S., Mune, T., Kaku, K., Kaneto, H., Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor. Diab. Vasc. Dis. Res., 1479164117725898, 2017.
5. Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V.F., Keane, K.N., Egan, L., Mamotte, C., Stokes, R., Gunton, J.E., Bittencourt, P.I.H., Newsholme, P., GLP-1 receptor signalling promotes beta-cell glucose metabolism via mTOR-dependent HIF-1alpha activation. Sci. Rep., 7, 2017, 2661.
6. Kim, S., Jung, J., Kim, H., Heo, R.W., Yi, C.O., Lee, J.E., Jeon, B.T., Kim, W.H., Hahm, J.R., Roh, G.S., Exendin-4 improves nonalcoholic fatty liver disease by regulating glucose transporter 4 expression in ob/ob mice. Korean J Physiol. Pharmacol. 18 (2014), 333–339.
7. Kazafeos, K., Incretin effect: GLP-1, GIP, DPP4. Diabetes Res. Clin. Pract. 93:Suppl. 1 (2011), S32–36.
8. Storgaard, H., Cold, F., Gluud, L.L., Vilsboll, T., Knop, F.K., Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes. Metab. 19 (2017), 906–908.
9. Drucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
10. Singh, S., Wright, E.E. Jr., Kwan, A.Y., Thompson, J.C., Syed, I.A., Korol, E.E., Waser, N.A., Yu, M.B., Juneja, R., Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes. Metab. 19 (2017), 228–238.
11. Matsumoto, S., Yamazaki, M., Kadono, M., Iwase, H., Kobayashi, K., Okada, H., Fukui, M., Hasegawa, G., Nakamura, N., Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J. Clin. Biochem. Nutr. 53 (2013), 68–72.
12. Kramer, C.K., Zinman, B., Choi, H., Connelly, P.W., Retnakaran, R., The impact of chronic Liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. J. Clin. Endocrinol. Metab. 100 (2015), 3702–3709.
13. Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., Stoffel, M., A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432 (2004), 226–230.
14. Huat, T.J., Khan, A.A., Abdullah, J.M., Idris, F.M., Jaafar, H., MicroRNA expression profile of neural progenitor-like cells derived from rat bone marrow mesenchymal stem cells under the influence of IGF-1, bFGF and EGF. Int. J. Mol. Sci. 16 (2015), 9693–9718.
15. Bao, X., Zhu, X., Liao, B., Benda, C., Zhuang, Q., Pei, D., Qin, B., Esteban, M.A., MicroRNAs in somatic cell reprogramming. Curr. Opin. Cell Biol. 25 (2013), 208–214.
16. Li, Y., Xu, X., Liang, Y., Liu, S., Xiao, H., Li, F., Cheng, H., Fu, Z., miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression. Int. J. Clin. Exp. Pathol. 3 (2010), 254–264.
17. Liu, P., Feng, Y., Dong, C., Liu, D., Wu, X., Wu, H., Lv, P., Zhou, Y., Study on therapeutic action of bone marrow derived mesenchymal stem cell combined with vitamin E against acute kidney injury in rats. Life Sci. 92 (2013), 829–837.
18. Zhao, L., Feng, Y., Chen, X., Yuan, J., Liu, X., Chen, Y., Zhao, Y., Liu, P., Li, Y., Effects of IGF-1 on neural differentiation of human umbilical cord derived mesenchymal stem cells. Life Sci. 151 (2016), 93–101.
19. Liu, P., Feng, Y., Dong, D., Liu, X., Chen, Y., Wang, Y., Zhou, Y., Enhanced renoprotective efect of IGF-1 modifed human umbilical cord-derived mesenchymal stem cells on gentamicin-induced acute kidney injury. Sci. Rep., 20287, 2016.
20. Liu, P., Cai, J., Dong, D., Chen, Y., Liu, X., Wang, Y., Zhou, Y., Effects of SOX2 on proliferation, migration and adhesion of human dental pulp stem cells. PLoS One, 10, 2015, e0141346.
21. Tao, S., Liu, P., Luo, G., Rojo de la Vega, M., Chen, H., Wu, T., Tillotson, J., Chapman, E., Zhang, D.D., p97 negatively regulates NRF2 by extracting ubiquitylated NRF2 from the KEAP1-CUL3 E3 complex. Mol. Cell. Biol., 37, 2017 (e00660–16).
22. Qureshi, F.M., Dejene, E.A., Corbin, K.L., Nunemaker, C.S., Stress-induced dissociations between intracellular calcium signaling and insulin secretion in pancreatic islets. Cell Calcium 57 (2015), 366–375.
23. Efanov, A.M., Zaitsev, S.V., Mest, H.J., Raap, A., Appelskog, I.B., Larsson, O., Berggren, P.O., Efendic, S., The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic beta-cells in the absence of modulation of K(ATP) channel activity. Diabetes 50 (2001), 797–802.
24. Hals, I.K., Singh, R., Ma, Z., Scholz, H., Bjorklund, A., Grill, V., Culture at low glucose up-regulates mitochondrial function in pancreatic beta cells with accompanying effects on viability. Islets 8 (2016), 165–176.
25. Keller, D.M., Clark, E.A., Goodman, R.H., Regulation of microRNA-375 by cAMP in pancreatic beta-cells. Mol. Endocrinol. 26 (2012), 989–999.
26. Yan, J.W., Lin, J.S., He, X.X., The emerging role of miR-375 in cancer. Int. J. Cancer 135 (2014), 1011–1018.
27. Hinnen, D., Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 30 (2017), 202–210.
28. Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjoth, T.V., Andreasen, A.H., Jensen, C.B., DeFronzo, R.A., N.N.S. Group, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
29. Inoue, K., Maeda, N., Fujishima, Y., Fukuda, S., Nagao, H., Yamaoka, M., Hirata, A., Nishizawa, H., Funahashi, T., Shimomura, I., Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol. Metab. Syndr., 6, 2014, 95.
30. Mateos, J.L., Wajchenberg, B.L., Liraglutide: new results in the treatment of type 2 diabetes mellitus. Drugs Today 48:Suppl. B (2012), 1–17.
31. Abdulreda, M.H., Rodriguez-Diaz, R., Caicedo, A., Berggren, P.O., Liraglutide compromises pancreatic beta cell function in a humanized mouse model. Cell Metab. 23 (2016), 541–546.
32. Araki, E., Oyadomari, S., Mori, M., Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp. Biol. Med. 228 (2003), 1213–1217.
33. Larque, C., Velasco, M., Navarro-Tableros, V., Duhne, M., Aguirre, J., Gutierrez-Reyes, G., Moreno, J., Robles-Diaz, G., Hong, E., Hiriart, M., Early endocrine and molecular changes in metabolic syndrome models. IUBMB Life 63 (2011), 831–839.
34. Li, X., MiR-375, a microRNA related to diabetes. Gene 533 (2014), 1–4.
35. Walker, M.D., Role of MicroRNA in pancreatic beta-cells: where more is less. Diabetes 57 (2008), 2567–2568.
36. El Ouaamari, A., Baroukh, N., Martens, G.A., Lebrun, P., Pipeleers, D., van Obberghen, E., miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57 (2008), 2708–2717.
37. Cheng, L., Zhan, B., Luo, P., Wang, B., miRNA375 regulates the cell survival and apoptosis of human nonsmall cell carcinoma by targeting HER2. Mol. Med. Rep. 15 (2017), 1387–1392.
38. Wang, L., Song, G., Liu, M., Chen, B., Chen, Y., Shen, Y., Zhu, J., Zhou, X., MicroRNA-375 overexpression influences P19 cell proliferation, apoptosis and differentiation through the notch signaling pathway. Int. J. Mol. Med. 37 (2016), 47–55.
39. Jia, L., Zhang, S., Huang, Y., Zheng, Y., Gan, Y., Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR375. Oncol. Rep. 37 (2017), 305–312.